Matthias Büttner1,2, Laura D Locati3, Monica Pinto4, Cláudia Araújo5, Iwona M Tomaszewska6, Naomi Kiyota7, E Vidhubala8, Christine Brannan9, Eva Hammerlid10, Olga Husson11, Dina Salem12, Georgios Ioannidis13, Eva Gamper14, Juan Ignacio Arraras15, Guy Andry16, Johanna Inhestern17, Juliane Theurer18, Katherine Taylor1,2, Susanne Singer1,2. 1. Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center Mainz, Mainz, Germany. 2. University Cancer Centre, Mainz, Germany. 3. Head & Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 4. Rehabilitation Medicine Unit, Strategic Health Services Department, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy. 5. Service of Surgical Oncology, Instituto Português do Oncologia do Porto Francisco Gentil, Porto, Portugal. 6. Department of Medical Education, Jagiellonian University Medical College, Krakow, Poland. 7. Department of Medical Oncology and Hematology, Cancer Center, Kobe University Hospital, Kobe, Japan. 8. Nellai Cancer Care Center, Tirunelveli, Tamil Nadu, India. 9. Mount Vernon Cancer Centre, East & North Herts NHS Trust, Northwood, London, UK. 10. Department of Otorhinolaryngology-Head and Neck Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden. 11. Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands. 12. Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. 13. Oncology Department, Nicosia General Hospital, Nicosia, Cyprus. 14. Department of Nuclear Medicine, Department of Psychiatry, Psychotherapy, and Psychosomatic Medicine, Psychiatry II Medical University of Innsbruck, Innsbruck, Austria. 15. Oncology Departments, Complejo Hospitalario de Navarra, Pamplona, Spain. 16. Surgery Department, Jules Bordet Institute, Brussels, Belgium. 17. Clinic of Otorhinolaryngology, Oberhavel Kliniken, Hennigsdorf, Germany. 18. Department of Surgery, University Medical Center Mainz, Mainz, Germany.
Abstract
PURPOSE: Surgical complications such as hypoparathyroidism (HPT) or vocal cord palsy are seldom assessed when the quality of life (QOL) in thyroid cancer patients is investigated. The aim of this study was to measure the QOL difference in thyroid cancer survivors with and without HPT. METHODS: Participants for this analysis were enrolled in 13 countries from a study that pilot-tested a thyroid cancer-specific QOL instrument. They were included if they had been diagnosed with thyroid cancer at least 9 months previously. QOL was measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) and some items on HPT symptoms (eg, tingling in fingers or toes). HPT status and other clinical data were extracted from the patients' medical charts. Comparisons of QOL domains between patients with and without HPT were performed using Mann-Whitney U test. The occurrence of HPT-related symptoms was compared using chi-square tests. Multiple ordinal regression analysis was performed to evaluate factors that might affect QOL. RESULTS: Eighty-nine patients participated in this study, 17 of whom were considered to have HPT. Patients in the HPT group reported significantly reduced QOL in 9 of the 15 scales of the EORTC QLQ-C30 compared to patients without HPT. Regression analysis showed that HPT was independently negatively associated with various scales of the QLQ-C30. Both groups showed a high prevalence of typical HPT symptoms. CONCLUSION: Thyroid cancer patients with HPT report significantly impaired QOL compared to thyroid cancer survivors without HPT. The assessment of HPT should be considered when measuring QOL in thyroid cancer patients.
PURPOSE: Surgical complications such as hypoparathyroidism (HPT) or vocal cord palsy are seldom assessed when the quality of life (QOL) in thyroid cancerpatients is investigated. The aim of this study was to measure the QOL difference in thyroid cancer survivors with and without HPT. METHODS: Participants for this analysis were enrolled in 13 countries from a study that pilot-tested a thyroid cancer-specific QOL instrument. They were included if they had been diagnosed with thyroid cancer at least 9 months previously. QOL was measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) and some items on HPT symptoms (eg, tingling in fingers or toes). HPT status and other clinical data were extracted from the patients' medical charts. Comparisons of QOL domains between patients with and without HPT were performed using Mann-Whitney U test. The occurrence of HPT-related symptoms was compared using chi-square tests. Multiple ordinal regression analysis was performed to evaluate factors that might affect QOL. RESULTS: Eighty-nine patients participated in this study, 17 of whom were considered to have HPT. Patients in the HPT group reported significantly reduced QOL in 9 of the 15 scales of the EORTC QLQ-C30 compared to patients without HPT. Regression analysis showed that HPT was independently negatively associated with various scales of the QLQ-C30. Both groups showed a high prevalence of typical HPT symptoms. CONCLUSION:Thyroid cancerpatients with HPT report significantly impaired QOL compared to thyroid cancer survivors without HPT. The assessment of HPT should be considered when measuring QOL in thyroid cancerpatients.
Authors: L Mazoni; A Matrone; M Apicella; F Saponaro; S Borsari; E Pardi; B Cosci; I Biagioni; P Rossi; F Pacciardi; A Scionti; R Elisei; C Marcocci; F Cetani Journal: J Endocrinol Invest Date: 2021-10-12 Impact factor: 4.256
Authors: Elizabeth J de Koster; Olga Husson; Eveline W C M van Dam; G Sophie Mijnhout; Romana T Netea-Maier; Wim J G Oyen; Marieke Snel; Lioe-Fee de Geus-Oei; Dennis Vriens Journal: Endocr Connect Date: 2022-07-19 Impact factor: 3.221